Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

9. Check if this filing amends a previously filed version of this report

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

H.R. 2617: Consolidated Appropriations Act, 2023 (P.L. 117-328)
H.R. 5376: Inflation Reduction Act of 2022 (P.L. 117-169)
H.R. 6833: Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (P.L. 117-180)
S. 4543: James M. Inhofe National Defense Authorization Act for Fiscal Year 2023
H.R. ____: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024
H.R. ____: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024
H.R.___: National Defense Authorization Act for Fiscal Year 2024
S._____: National Defense Authorization Act for Fiscal Year 2024
S._____: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024
S. ____: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024
FY 2024 Presidents Budget Request

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

S. 79: Interagency Patent Coordination and Improvement Act of 2023 - Provisions related to Interagency Task Force
S. 142: Preserve Access to Affordable Generics and Biosimilars Act - Provisions related to patent settlements
S. 150: Affordable Prescriptions for Patients Act of 2023 - Provisions related to intellectual property and patents
S. 574: Increasing Prescription Drug Competition Act - Patent-related policy issues
Biopharmaceutical innovation and patent policy issues
Bayh-Dole march-in rights policy issues
Patent thicket policy issues
Patent use codes policy issues

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

H.R. 198: Drug Pricing Transparency and Accountability Act - Provisions related to the 340B Program
H.R. 1790: Biologics Competition Act of 2023 - Directs the Secretary of Health and Human Services to evaluate the extent to which the substitution of interchangeable biological products is impacted by differences between the system for determining a biological product to be interchangeable and the system for assigning therapeutic equivalence ratings to drugs, and for other purposes
H.R. 4390: Protect 340B Act - Provisions related to 340B Program
H.R. 5376: Inflation Reduction Act of 2022 (P.L. 117-169)
H.R. 7032: Increasing Transparency in Generic Drug Application Act - Requires the Food and Drug Administration to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why)
S. 148: Stop STALLING Act - Provisions related to citizen petitions
S. 315: Taxpayer Research And Contributions Knowledge Act of 2023 or TRACK Act of 2023 - Directs the Secretary of Health and Human Services and other Federal officials to compile into a searchable database information relating to Federal support for biomedical research and development, and for other purposes
S. 898: Fair Accountability and Innovative Research Drug Pricing Act of 2021 - Provisions related to drug pricing
S. 2076: PASTEUR Act of 2021 - Provisions related to antimicrobial resistance policy issues
S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics Act or PREVENT Pandemics Act
Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA)
Cancer Moonshot Initiative
21st Century Cures 2.0
Drug cost and pricing policy issues
Principles for drug pricing reform
Drug importation policy issues
Competition policy issues
Orphan Drug Act policy issues
Antimicrobial resistance (AMR) policy issues
Mental health policy issues
High deductible health plans/HSA policy issues
Supply chain and foreign manufacturing policy issues
Real world evidence policy issues
Clinical trial diversity policy issues
Prescription drug abuse policy issues
340B drug discount program policy issues
Patient assistance program policy issues
Biosimilar approval and reimbursement policy issues
Drug shortages policy issues
COVID-19 policy issues
Pandemic preparedness policy issues
Defense Production Act policy issues

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

H.R. 485: Protecting Health Care for All Patients Act of 2023 - Prohibits all federal health care programs from using prices that are based on quality-adjusted life years to determine relevant thresholds for coverage, reimbursements, or incentive programs
H.R. 830: Help Ensure Lower Patient Copays Act or the HELP Copays Act - Requires health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements
H.R. 5376: Inflation Reduction Act of 2022 (P.L. 117-169)
S. 127: Pharmacy Benefit Manager Transparency Act of 2023 - Provisions related to PBMs
National coverage determination policy issues
Part D redesign and policy issues including non-interference and rebates policy issues
Part B policy issues
Drug cost and pricing policy issues
Rebate policy issues
Insulin policy issues
Pharmacy Benefit Manager reform and policy issues
Value-based purchasing arrangements policy issues
Anti-Kickback Statute policy issues
Center for Medicare and Medicaid Innovation (CMMI) and model policy issues
Medicaid rebates and waiver policy issues
CMS Guidance on the Medicare Drug Price Negotiation Program: Initial Memorandum [ ] IPAY 2026 and Solicitation of Comments
CMS Guidance on Medicare Part B and D Inflation Rebates

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TRD

16. Specific lobbying issues

S. 113: Prescription Pricing for the People Act of 2023 - Provisions related to medical supply chains and prescription drug pricing transparency policy issues
S. 2495: Protecting our Pharmaceutical Supply Chain from China Act of 2021 - Provisions related to medical supply chain policy issues
Biopharmaceutical innovation policy issues
International intellectual property and market access policy issues
Pricing and reimbursement policy issues
Supply chain policy issues
WTO TRIPS waiver policy issues
China outbound investment policy issues

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

22. New General description of client’s business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address: http://www.phrma.org/about/members

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
No Yes